News headlines about Bioline RX (NASDAQ:BLRX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioline RX earned a news impact score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.5261827338861 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media stories that may have impacted Accern’s analysis:

Several research analysts recently weighed in on BLRX shares. Zacks Investment Research raised Bioline RX from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Tuesday, October 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Bioline RX in a research report on Tuesday, September 26th. Oppenheimer set a $3.00 target price on Bioline RX and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Maxim Group set a $3.00 target price on Bioline RX and gave the stock a “buy” rating in a research report on Monday, December 4th. Finally, ValuEngine raised Bioline RX from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.88.

Bioline RX (BLRX) opened at $1.11 on Friday. Bioline RX has a 52-week low of $0.80 and a 52-week high of $1.38. The company has a market capitalization of $117.96, a PE ratio of -3.36 and a beta of 0.88.

Bioline RX (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, November 21st. The biotechnology company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). analysts anticipate that Bioline RX will post -0.25 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at

Bioline RX Company Profile

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Insider Buying and Selling by Quarter for Bioline RX (NASDAQ:BLRX)

Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with's FREE daily email newsletter.